FDA Fuels Opioid Addiction Crisis With New Opioid 10 Times More Powerful Than Fentanyl, Experts Say New Drug Dsuvia Will Kill People

The Food and Drug Administration (FDA) has approved a new opioid that is times more powerful than Fentanyl, a highly addictive opioid.

According to STAT News, the new drug is Dsuvia, a tablet  that is placed under the tongue with an applicator.

Dsuvia was reportedly created by AcelRx Pharmaceuticals and the Department of Defense for wounded soldiers on the battlefield, not the general public, who are going to be consuming the drug.

The mostly white FDA advisory committee recommended approval in October despite the national opioid addiction crisis, which President Donald Trump blames on Mexico.

Dr. Andrew Kolodny, head of the Opioid Policy Research Collaborative at Brandeis University, slammed FDA Commissioner Scott Gottlieb (pictured above):

If Gottlieb meant business when he endorsed the report — if he was speaking truthfully when he promised Congress that he would fix FDA’s past mistakes — then he would not have allowed this product on the market.

Rather than approving new exceptionally dangerous opioid formulations, he would be pulling the most dangerous opioids off the market.

There is absolutely no need for this product. Claiming we need it on the market to help soldiers on the battlefield is ridiculous. We already have sublingual fentanyl product available for use on the battlefield.

Dr. Sidney Wolfe, senior adviser at Public Citizen Health Research Group, said the new drug will kill people:

It is certain that Dsuvia will worsen the opioid epidemic and kill people needlessly. It will be taken by medical personnel and others for whom it has not been prescribed. And many of those will overdose and die.

(Source: STAT News, Photo Credit: U.S. Department of Agriculture/Flickr)

About The Author

You might be interested in

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *

Get the latest breaking news video clips before everyone else with our newsletter! We do not share or sell your email address with anyone.